newsfilter
← Earnings
Earnings Releases·

Arvinas — Third Quarter 2026 Earnings Summary

  • Revenue dropped to $0.5 million from $41.9 million year-over-year due to the non-recurrence of Pfizer collaboration revenue, while GAAP net loss widened to $53.9 million from $35.1 million despite R&D and G&A expenses declining to $46.9 million and $12.6 million, respectively.
  • Cash and marketable securities decreased by $126.5 million to $558.9 million, yet management confirms these funds are sufficient to cover operating and capital expenditure requirements through the second half of 2028.
  • Clinical outlook remains focused on data releases for ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, with ARV-102 Phase 1b trial initiation expected in the EU and UK in 2027 while the U.S. IND remains on hold.
  • Strategic shifts include the cessation of Pfizer revenue following the Rigel License Agreement and a reduction in external R&D expenses driven by a $14.2 million decrease in the vepdegestrant (ARV-471) program, partially offset by increased spending on ARV-027, ARV-6723, and ARV-393.
Company
ARVINAS INC
Sector
Healthcare
Industry
Biotechnology